A detailed history of Aqr Capital Management LLC transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Aqr Capital Management LLC holds 98,081 shares of SRRK stock, worth $4.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
98,081
Previous 39,754 146.72%
Holding current value
$4.31 Million
Previous $331,000 137.16%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.63 - $9.71 $445,035 - $566,355
58,327 Added 146.72%
98,081 $785,000
Q2 2024

Aug 14, 2024

BUY
$7.84 - $16.79 $231,178 - $495,086
29,487 Added 287.2%
39,754 $331,000
Q1 2024

May 15, 2024

BUY
$13.2 - $17.76 $135,524 - $182,341
10,267 New
10,267 $182,000
Q3 2023

Nov 14, 2023

BUY
$6.02 - $7.76 $62,415 - $80,455
10,368 New
10,368 $73,000
Q3 2022

Nov 14, 2022

BUY
$5.33 - $11.3 $75,334 - $159,714
14,134 New
14,134 $98,000
Q4 2021

Feb 14, 2022

SELL
$24.14 - $35.18 $205,648 - $299,698
-8,519 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$27.38 - $42.21 $57,142 - $88,092
-2,087 Reduced 19.68%
8,519 $281,000
Q2 2021

Aug 16, 2021

SELL
$26.34 - $46.62 $11,984 - $21,212
-455 Reduced 4.11%
10,606 $307,000
Q1 2021

May 17, 2021

SELL
$45.96 - $68.02 $127,033 - $188,007
-2,764 Reduced 19.99%
11,061 $560,000
Q4 2020

Feb 16, 2021

BUY
$13.72 - $51.57 $189,679 - $712,955
13,825 New
13,825 $671,000
Q4 2019

Feb 14, 2020

SELL
$7.2 - $13.2 $177,048 - $324,588
-24,590 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$8.95 - $15.72 $220,080 - $386,554
24,590 New
24,590 $220,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.27B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.